Theravance Biopharma’s (TBPH) “Buy” Rating Reaffirmed at Piper Jaffray Companies

Piper Jaffray Companies restated their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note issued to investors on Monday, TipRanks reports.

Several other equities research analysts have also recently weighed in on TBPH. BidaskClub upgraded shares of Theravance Biopharma from a hold rating to a buy rating in a research note on Wednesday, September 4th. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the company a buy rating in a research note on Friday, August 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $44.25.

NASDAQ:TBPH traded down $0.01 during trading hours on Monday, hitting $23.77. 278,300 shares of the company traded hands, compared to its average volume of 247,635. Theravance Biopharma has a twelve month low of $15.18 and a twelve month high of $35.48. The firm has a 50-day moving average of $20.88 and a 200 day moving average of $20.65. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -5.96 and a beta of 1.72.



Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.50. Theravance Biopharma had a negative net margin of 369.67% and a negative return on equity of 2,631.15%. The company had revenue of $26.15 million for the quarter, compared to analyst estimates of $13.92 million. On average, analysts expect that Theravance Biopharma will post -4.28 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. DekaBank Deutsche Girozentrale boosted its stake in Theravance Biopharma by 64.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $306,000 after buying an additional 7,500 shares in the last quarter. Fosun International Ltd increased its holdings in Theravance Biopharma by 78.0% in the 2nd quarter. Fosun International Ltd now owns 185,899 shares of the biopharmaceutical company’s stock valued at $2,967,000 after buying an additional 81,434 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of Theravance Biopharma by 882.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,965 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 8,951 shares in the last quarter. CWM Advisors LLC acquired a new position in shares of Theravance Biopharma in the 2nd quarter valued at $167,000. Finally, SG Americas Securities LLC bought a new position in shares of Theravance Biopharma during the 1st quarter worth about $156,000. Institutional investors and hedge funds own 84.16% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Featured Article: Is it better to buy a fund with a higher or lower NAV?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.